

Collaboration to Improve Population Health, Driven by Comparative Clinical Analytics



American Medical Group Association

AMGA supports its members in enhancing population health and care for patients through integrated systems of care.

Founded in 1949

- 420+ member organizations
- 125,000+ physicians
- Provide health care to more than 130 million patients per year, in 49 states
- Two-thirds of members are integrated delivery systems—up from one-third, 5 years ago
- Average group size is 300 physicians, median 130 physicians
- Patient-centered, team-based care—emphasis on care coordination
- Continuous performance improvement—systems thinkers
- Leadership on EHR and eRx adoption
- Leadership on Accountable Care—emphasis on value, in terms of population health



Parallel AMGA Strategies

- Advocacy: Redesign payment system to align incentives around population health
 - Volume \rightarrow Value
 - ACO \rightarrow High-Performing Health System definition
- Support members in redesigning the delivery system to manage population health
 - Devise strategies for moving from one payment model to another
 - Develop competencies in understanding and managing population health
 - Provide data resources and analytical tools \rightarrow Humedica partnership
 - Extend AMGA's model for shared learning → Anceta









American Medical Group Association

AMGA subsidiary, created to extend AMGA's model for shared learning, based on comparative clinical analytics

Anceta's partner, a next-generation clinical informatics company, based in Boston

Recently became part of OptumInsight

"Data factory" — extract and integrate clinical and administrative data, across the continuum of care

Disease-specific analytic models, including predictive analytics

Clinical analytics solution, Humedica MinedShare®

Where's the Opportunity?

■ 10% of the population consumes 64% of healthcare dollars (blue); 5% consumes 49%



Source: Conwell LJ, Cohen JW. Characteristics of people with high medical expenses in the U.S. civilian non-institutionalized population, 2002. Statistical Brief 73. March 2005. Agency for Healthcare Research and Quality, Rockville, MD. Data from Medical Expenditure Panel Survey (MEPS).

- Hospital admission often represents a failure of ambulatory care
- Typical Medicare patient sees 7 different physicians every year—2 PCPs, 5 specialists
 - Critical need for care coordination

Article

Annals of Internal Medicine

Primary Care Physicians' Links to Other Physicians Through Medicare Patients: The Scope of Care Coordination

Hoangmal H. Pham, MD, MPH; Ann S. O'Malley, MD, MPH; Peter B. Bach, MD, MAPP; Cynthia Salontz-Martinez, ScM; and Deborah Schrag, MD, MPH

Background: Primary care physicians are expected to coordinate care for their patients.

Objective: To assess the number of physician peers providing care to the Medicare patients of a primary care physician.

Design: Cross-sectional analysis of claims data.

Setting: Fee-for-service Medicare in 2005.

Participants: 2284 primary care physicians who responded to the 2004 to 2005 Community Tracking Study Physician Survey.

Measurements: Primary patients for each physician were defined as beneficiaries for whom the physician billed for more evaluation and management visits than any other physician in 2005. The number of physician peers for each physician was the sum of other unique physicians that the index physician's primary patients visited plus other unique physicians who served as the primary physician for each of the index physician's nonprimary patients during 2005.

Results: The typical primary care physician has 229 (interquartile range, 125 to 340) other physicians working in 117 (interquartile range, 66 to 175) practices with which care must be coordinated, equivalent to an additional 99 physicians and 53 practices for every

100 Medicare beneficiaries managed by the primary care physician. When only the 31% of a primary care physician's primary patients who had 4 or more chronic conditions was considered, the median number of peers involved was still substantial (86 physicians in 36 practices). The number of peers varied with geographic region, practice type, and reliance on Medicaid revenues.

Limitations: Estimates are based only on fee-for-service Medicare patients and physician peers, and the number of peers is therefore probably an underestimate. The modest response rate of the Community Tracking Study Physician Survey may bias results in unpredictable directions.

Conclusion: In caring for his or her own primary and nonprimary patients during a single year, each primary care physician potentially must coordinate with a large number of individual physician colleagues who also provide care to these patients.

Funding: National Institute on Aging, American Medical Group Association, and the Robert Wood Johnson Foundation.

Ann Intern Med. 2009;150:236-242. For author affiliations, see end of text.

www.annals.org

Current care systems cannot do the job. Trying harder will not work. Changing systems of care will.

 Crossing the Quality Chasm Institute of Medicine, 2001

could greatly improve outcomes, is currently very fragmented. Beneficiaries typically see 7 different physicians

Anceta Collaborative

Use data to identify opportunities for improvement and "best" performance

- Medical groups: Humedica MinedShare[®]
- Anceta: provocative analyses
- Learn "the rest of the story" from other medical groups

Finding "best" performance

- Current: Incidental observations, clinical intuition
- Future: Systematic exploration—regression models
- Expanding scope
 - Detailed models for chronic disease
 - All active patients—Adult preventive services, Population management dashboard
 - Adjudicated claims data—all covered services

Once you move away from the push of information to the pull of learning, you liberate creative powers in your people.

The New Social Learning
 Tony Bingham and Marcia Conner

Diabetes Hypertension Dyslipidemia Coronary Artery Disease COPD Congestive Heart Failure Pediatric Asthma

Prevalence of Chronic Conditions

- 20 medical groups, 7.0 million patients, age 18–89, who had an ambulatory visit in 2011 or 2012
- Left: Proportion of patients who fall into each combination of Humedica disease cohorts
- Right: Total ambulatory wRVUs for the patients who fall into each combination of cohorts

Patients by Disease Cohort

Ambulatory Work RVUs by Disease Cohort

None DYL HTN None 29.3% 45.5% DYL HTN DM DYL HTN HTN DM COPD COPD DYL HTN DYL HTN DM DYL DM CAD CAD DYL DYL HTN DM DYL HTN DYL DYL HTN DM CAD DYL DM HTN COPD CHF HTN DM DM COPD DYL HTN DYL HTN DM DYL HTN DM COPD CAD CHF COPD CAD CAD DYL HTN CHF DYL DYL DM CAD CAD COPD DYL HTN CHF DYL HTN DM CAD DYL DYL HTN DYL DYL COPD HTN DM HTN DYL ITN DM DYL DYL CAD PAS CHF DM.. co.. HTN HTN.. ΗТ... DYL HTN DM CHF DM COPD CAD HTN DYL CHF Н.... COP HTN DYL HTN HTN DYL HTN DM DYL HTN D DM. D.... Н... DYL CAD DYL DM COPD ΗТ COPD HT D HTN DYL Ν COP... PAS DHHHD H... DY DYL HTN CAD DYL DYL D COPD D DYL D... LD D HTN COPD CA HTN HTN HTN COPD. DY.. D CHF CAD.

- CAD **Coronary Artery Disease** Diabetes DM Dyslipidemia DYL HTN Hypertension COPD Chr. Obstr. Pulm. Disease CHF **Congestive Heart Failure**
- PAS Pediatric Asthma

Prevalence of Chronic Conditions

- 20 medical groups, 7.0 million patients, age 18–89, who had an ambulatory visit in 2011 or 2012
- Left: Proportion of patients who fall into each combination of Humedica disease cohorts
- Right: Total ambulatory wRVUs for the patients who fall into each combination of cohorts

Patients by Disease Cohort

Ambulatory Work RVUs by Disease Cohort





Chronic Conditions – Pct. of Amb. wRVUs

- 20 medical groups, 7.0 million patients, age 18–89, who had an ambulatory visit in 2011 or 2012
- Total ambulatory wRVUs for the patients who fall into each combination of cohorts
- All combinations involving hypertension are colored red

CAD Coronary Artery Disease
DM Diabetes
DYL Dyslipidemia
HTN Hypertension
COPD Chr. Obstr. Pulm. Disease
CHF Congestive Heart Failure

PAS Pediatric Asthma

		AP	CG	DX	EB	FX	GW	GX	HM	IM	JD	KL	NC	PT	RL	RS	SK	UC	WF	XZ	ZJ
Non	e	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	
				DYL HTN DM		DYL HTN	HTN	DYL HTN DM	DYL HTN		DYL HTN	HTN		DM	DYL HTN	DYL HTN			HTN		None
DYL HTN	DYL HTN DM		DYL HTN				DYL HTN DM	DYL HTN	DYL HTN DM	DYL HTN	HTN	DYL HTN	DYL HTN	DYL HTN	DYL HTN DM		DYL HTN		DYLHTN	DYL HTN	
		DYL HTI DM		DYL HTN	DYL HTN	HTN	DYL HTN	HTN	HTN	DYL HTN DM	DYL HTN DM	DYL HTN DM	HTN	HTN	DYL	DYL	HTN	DYL HTN	DYL HTN DM	DYL HTN DM	
HTN	DYL		DYL	HTN	DYL	DYL	DYL DYL HTN DM CAD DYL HTN	DYL HTN DM CAD	DYL	HTN	DYL DYL HTN DM CAD	DYL DYL HTN DM CAD	DYL HTN DM	DYL HTN DM CAD	HTN DYL HTN	DYL HTN DM	DYL	HTN	DYL DYL HTN	HTN	HTN
DYL HTN DM DY CAD 0	LHTN HTN CAD DM	DYL D HTN L D H.	DYL HTN DM	DYL DYL HTN DM CAD	DYL HTN DM	DYL DY HTN L DM HT DYL DYL HT H	DYL DY HTN L CAD HT HTN DYL	DYL HTN HT DM DM	DYL HTN DM CAD DYL HTN CAD	DYL DYL DY	DYL HTN CAD DYL DYL HTN HT COP N	DYL DTL HTN DM CAD C HTN DY DM L	DYL DYL DYL HTN HTN	DYL HTN DM COPD DYL HTN CAD DYL DYL	DYL HTN CAD DYL HTN	HTN DYL HTN DM CAD	DYL HTN DM DYL DY	DYL HTN DM	DM COPD DYL DYL HTN HTN COP DM D C	DYL DYL HTN HT	DYL HTN
DYL HTN DM COPD	HTN DYL COPD DYL	DYL DY HTN HT D CA COP DY D D	L HTN N DYL DY L DM H	DYL DM DM N DYL HTN H DM	HTN DYL DYL DM H	COP D HTN DM H H H H H H H	DM H DYL DYL HT H D C	DYL DYL HTN HTN CAD C DYL DYL HT DM	DYL DYL DM H HTN DYL DM H	HIN L DM HT CAD N C DYL HTN DM DM	D D HTN COP DM D DYL CO HT PD	H DYL DY HT L H H D	DM CA CAD D DYL HT DM N D D D	HTN HTN D D DYL DY HTN L CO HT	DYL DYL HT H DYL DYL DYL DYL DM H	DYL DY HTN L CAD DM HTN DYL DM H	HTNLCADHTHTNDYDMLDYDM	DYL DYL DYL HT H	COP D DYL HT	DM CAD DM DM HT N	
DYL HTN COPD COPD DYL DM	Y D DY HT Y D DY HT C HT C D HT C D D	HTN H C N. DY D L H Y DY D	DYL DY HT L H DM DY DY H C	DYL DY HT L DY D H D D C	DYL HT HT N DY D C DY D H	DY D D LHYYY D D D DY D D	D D D H DY D D D H D C	HT C D D D DY P H	DY D DY D H DY D D	HT H DY D D L Y M HT D D	D D D D DY D H	DY D D L Y M C D D	D D D D H C D D	DYL DY DM L HT HT D D D	DYL DYL HT H HT D DY D D	DY D DY D D HT D D	DY C D DY HT D D D D	DM HT N D D DY H D	DYL DYL DM H DY D D L YL Y DY D H	HT L D DY D DY DY D D H D C	DY DY DY H D D C D
						C H H								D	H D D D C D D			DD P			

Current Anceta Participants

- Aurora Health Care Milwaukee, WI
- Baylor Quality Alliance—Dallas, TX
- Billings Clinic Billings, MT
- Brown & Toland Physicians San Francisco, CA
- Carilion Clinic Roanoke, VA
- Carolinas HealthCare System Charlotte, NC
- Colorado Springs Health Partners Colorado Springs, CO
- Community Physician Network Indianapolis, IN
- Cornerstone Health Care High Point, NC
- DuPage Medical Group Downers Grove, IL
- The Everett Clinic Everett, WA
- Florida Medical Clinic Zephyrhills, FL
- HealthEast St. Paul, MN
- Henry Ford Health System Detroit, MI
- Holston Medical Group (Apogee) Kingsport, TN
- The Iowa Clinic West Des Moines, IA
- Lahey Clinic Burlington, MA

- Mayo Clinic Health System Rochester, MN
- Mercy Health System St. Louis, MO
- Mid Hudson Medical Group Fishkill, NY
- Mount Kisco Medical Group Mount Kisco, NY
- Riverside Health System Newport News, VA
- Sentara Healthcare Norfolk, VA
- SwedishAmerican Health System Rockford, IL
- Wilmington Health Wilmington, NC



Anceta Interaction

- In-person meetings
 - Two dedicated collaborative meetings each year
 - Spring, after AMGA Annual Conference
 - Fall, coordinated with AMGA Institute for Quality Leadership/ACO Summit
 - Dedicated sessions at AMGA Annual Conference
- Webinars, between meetings
- Outreach and consultation by Anceta staff
 - Assist with data interpretation and supplemental analyses
 - Discover and document best practices
- Anceta Collaboration Portal
 - Collaborative materials, reference documents
 - Discussion forum (e-mail)

Typical Team for Collaborative Meetings

- Physician leader with an interest in process redesign
- Operational leader, nurse-manager, or "change agent"
- Quality analyst—how data reflect the process

Humedica's "Data Factory"



Data Normalization and Mapping

LOCAL NAME	LOCAL CODE	LOCAL NAME	LOCAL CODE
lisinolpril	53004	lisinopril 20MG	206330
lisinop 20mg	47650	LISINOPRIL 20MG	201887
lisinoplril	84479	lisinopril 20MG	170309
lisinoporil	114142	LISINOPRIL 20MG TABLETS	2619
lisinoprel	56844	Lisinopril 40	252035
lisinoprel 20mg	62959	lisinopril 40 mg	247971
LISINOPRIL	238488	LISINOPRIL 40 MG	223018
Lisinopril	233787	lisinopril 40 mg	58406
lisinopril 10mg	82991	LISINOPRIL 40 MG TABLET	185906
LISINOPRIL 30MG	88777	LISINOPRIL 40MG	99596
lisinopril 10 mg	244861	LISINOPRIL 40MG TABLETS	51301
LISINOPRIL 10 MG	180608	lisinopril 5 mg	252165
lisinopril 10 mg	180607	LISINOPRIL 5 MG	234939
LISINOPRIL 10 MG TABLET	235592	LISINOPRIL 5 MG TABLET	239699
lisinopril 10mg	129260	LISINOPRIL 5.0 mgmTABLETS	6035
LISINOPRIL 10MG	7667	lisinopril 5mg	17488
LISINOPRIL 10MG TABLETS	4217	LISINOPRIL 5MG TABLETS	103221
lisinopril 20	229320	LISINOPRIL MG TABLETS	9413
LISINOPRIL 20 MG	229300	LISINOPRIL TAB 2.5 MG U/D	924303
lisinopril 20 mg	227878	LISINOPRIL TAB 5 MG U/D	924305
LISINOPRIL 20 MG TABLET	189126	lisinopril tab 10 mg	127775
lisinopril 20mg	253427	LISINOPRIL TAB 10 MG U/D (PRINIVIL)	924306
lisinopril Tablet 5 mg	238564	LISINOPRIL TAB 20 MG U/D	924307
lisinopril tbs	125490	LISINOPRIL TAB 40 MG (EXP) (ZESTRIL)	924311
lisinoprol	17600	lisinopril tablet 20 mg	82047
lisinoril	83965	LISINORRIL	92141

Tools for Improving Population Health



Risk Stratification

10% of the population consumes 64% of healthcare dollars (blue); 5% consumes 49%



Statistical Brief 73. March 2005. Agency for Healthcare Research and Quality, Rockville, MD. Data from Medical Expenditure Panel Survey (MEPS).

- Hospital admission often represents a failure of ambulatory care
- Typical Medicare patient sees 7 different physicians every year—2 PCPs, 5 specialists
 - Critical need for care coordination

Humedica MinedShare[®] – Predictive Analytics

											User: jcuddeback_den	o@anceta.com	Log Out
-26	• HU	MED	CA Min	edShare®	Home	Dashboard	Value Matrix	Reports	Workspace				?
С	reate,	View, a	nd Edit (Graphs							Clear Workspace	🕀 Add Gra	iph 🔡
🛃 Pa	itients at Ri	isk of CHF-Re	lated Hospitaliza	ation w/in Next 6 Months, by Cli				📸 Cohort	Time Period	🍸 Filters (1)	🗠 Graph Settings	Hide Data	Actions 🔻
	Patient	ts at Risk of	CHF-Related H	Hospitalization w/in Next 6 Mc	nths, by Clinio	Ξ					Most Freque	nt Site of Care	
	1200							Most Frequent Site of Data]: 1892981420	Care [Last 24 Month	s of	116042497 189298142(2862927165 3496959779 3696308757 3958583993 3963505378	1	
ients	1000 800							Likelihood of CHF-relat months following end Data] Category: 90-94 (More)	ted Hospitalization w of data Categorized	vithin 6 [End of			
Number of Pat	600							Number of Patients : 8.4% = 103 (Number or CHF-related Hospitaliza following and of data (103 f Patients in this Likeli ation within 6 month	hood of			
	400 200				_			Category and Most Fre Months of Data] Categ Likelihood of CHF-relat months following end Data] Categories)	quent Site of Care [La ory) / 1224 (Total nur ted Hospitalization wi of data Categorized				
			0-79 (Least)		80-89 (L	.ess)		90-94 (More)		95+	(Most)		
Y					Likeliho	od	alization within 6 months foll	owing end of data Categorize	ed [End of Data]			# of pat	ients: 1612
D	ata Pa	atient List	Graph Notes										5 7 2 2
Clic	k on data i	n the graph a	bove or in the D	Data tak	patient list belo	ow.						103 record(s) re	eturned
Patie	ent ID			▲ Likelihood of CHF-	related Hospitalizatio	n within 6 months following e	end of data Cat Most Frequent S	ite of Care (Last 24 Months of Data	1]	Pts w CHF-Re	ated Amb Visit (Eval & Mgmt and/or Pr	oc) [In Time Period]	
00A	4B63038C0AEE	BB9155AC6		90-94 (More)			1892981420			Yes			^
00A9	96305134530E	5370177A9		90-94 (More)			1892981420			Yes			•
025	47.50498F/(D/)	08C7AB25AB		90-94 (Mole) 90-94 (Mole)			1892981420			Yes			
0404	9050F92R733C	87F4FF087		90-94 (More)			1892981420			Yes			
044	23B066EF436F	3B383D783B		90-94 (More)			1892981420			Yes			
04F0	016EF257FB68	9C4D5181F		90-94 (More)			1892981420			Yes			•
Cop	py selected	l Patient ID											
Dudiel, D											Comminist (a) 2008-2014	human tan Ing All	

CHF-Related Admissions and ED Visits



Humedica MinedShare® – Dashboard

Current Measure Status

	A1c	# of Pts	Result	Target	Comparator	% vs. Target	Last 12 Mos.		Combined
Г	Pts w/ 1 or more A1c tests	15,542	63.6%	65%	64.4%			Г	Pts w/ 1 or more SBP, DBP, LDL & A
•	Pts in Control (Last A1c < 7%)	9,880	57.1%	80%	51.9%				Pts in Control
	Pts in Control (Last A1c < 8%)	9,880	80.4%	75%	75.2%				Pts in Tight Control
	Pts w/ 2 or more A1c tests	15,542	39.9%	40%	39.9%				Mean # of Visits - High Risk Pts (Any
	Mean A1c Improvement	6,207	0.19	0.1	0.17	-			Mean # of Visits - High Risk Pts (All)
	Mean # of Visits for High Risk Pts (A1c > 9%)	900	7.9	5.5	5.5				Pts at High Risk: Any Metric
	Mean # of Visits for High Risk Pts (A1c > 11%)	247	7.8	5	5.1		~		Pts at High Risk: All Metrics
	Pts at High Risk (Last A1c > 9%)	9,880	9.1%	10%	13.1%		\sim		Resource Measures
	Pts at High Risk (Last A1c > 11%)	9,880	2.5%	5%	4.5%				Mean # of Any Amb Visits
	LDL	# of Pts	Result	Target	Comparator	% vs. Target	Last 12 Mos.		Mean # of E&M Visits
Г	Pts w/ 1 or more LDL tests	15,542	59.4%	60%	59.1%		2		Mean # of Amb Work RVUs
•	Pts in Control (Last LDL < 100 mg/dl)	9,226	62.8%	75%	62.7%				Mean # of Level 4/5 E&M Visits
	Mean LDL Improvement	4,257	8.5	6	6.4	-	\sim		Mean # of Non-Mid-Level E&M Vis
	Mean # of Visits for Higher Risk Pts	1,203	7.8	5.5	5.6			•	Costly DM Amb Rx Ratio
	Mean # of Visits for Highest Risk Pts	368	7.8	5.5	5.6				Pts w/ 1 or more ED/ER Visits
	Pts at High Risk (Last LDL > 130 mg/dl)	9,226	13%	15%	14.2%				Mean # of ED/ER Visits/1000 DM F
	Pts at High Risk (Last LDL > 160 mg/dl)	9,226	4%	5%	4.5%				Pts w/ 1 or more IP Visits
	SBP and DBP	# of Pts	Result	Target	Comparator	% vs. Target	Last 12 Mos.	•	Mean # of IP Visits/1000 DM Pts
	Pts w/ 1 or more SBP & DBP tests	15,542	78.7%	80%	81.1%		~		Mean Inpatient LOS
	Pts in Control (SBP/DBP < 130/80 mmHg)	12,236	38.4%	50%	39.4%		·····`		# of Pts w/ ICU/CCU Stay
	Pts in Control (SBP/DBP < 140/90 mmHg)	12,236	72.4%	70%	72%		~		Mean ICU/CCU LOS
	Mean SBP Improvement	9,811	1.7	2	2.1		\sim		Rate of Pts w/ 7-day Readmission
	Mean DBP Improvement	9,829	0.9	1	1.2			•	Rate of Pts w/ 30-day Readmissio
	Mean # of Visits for High Risk Pts	460	8	5	5.4				
	Pts at High Risk	12,236	3.8%	4.5%	4.4%		~~~~		
	Eye Exam	# of Pts	Result	Target	Comparator	% vs. Target	Last 12 Mos.		
	Pts w/ 1 or more eye exams	15,542	5.3%	3%	2.9%	+			
	Mean # of Visits for Pts w/o an eye exam	14,713	6.3	5	4.7				

Combined	# of Pts	Result	Target	Comparator	% vs. Target	Last 12 Mos.
Pts w/ 1 or more SBP, DBP, LDL & A1c tests	15,542	53%	55%	54.2%		~~
Pts in Control	8,242	14.6%	25%	15%		
Pts in Tight Control	8,242	39.3%	40%	38.2%		~
Mean # of Visits - High Risk Pts (Any)	1,773	8.6	5.9	5.9		
Mean # of Visits - High Risk Pts (All)	0	N/A	4	3.5		~
Pts at High Risk: Any Metric	8,242	21.5%	25%	25.2%		
Pts at High Risk: All Metrics	8,242	0%	0.1%	0%		
Resource Measures	# of Pts	Result	Target	Comparator	% vs. Target	Last 12 Mos.
Mean # of Any Amb Visits	15,542	9.8	7	7.3		
Mean # of E&M Visits	15,542	6.5	5	4.7		
Mean # of Amb Work RVUs	15,542	18.58	10	10.9		
Mean # of Level 4/5 E&M Visits	13,352	0.6	0.5	0.5	H	
Mean # of Non-Mid-Level E&M Visits	11,091	0.8	0.5	N/A		
Costly DM Amb Rx Ratio	8,537	0.5	0.8	0.5		
Pts w/ 1 or more ED/ER Visits	15,542	15.8%	14%	14.8%		
Mean # of ED/ER Visits/1000 DM Pts	15,542	261	300	260		
Pts w/ 1 or more IP Visits	15,542	11.9%	12%	11.9%		
Mean # of IP Visits/1000 DM Pts	15,542	194	75	194	-	
Mean Inpatient LOS	1,842	8.8	8	9.8	_	~~~~
# of Pts w/ ICU/CCU Stay	1,842	27%	25%	26.8%		\sim
Mean ICU/CCU LOS	1,842	1	1.5	1.4	-	~~~~
Rate of Pts w/ 7-day Readmission	1,842	8.5%	7.5%	7.3%		$\sim \sim \sim$
Rate of Pts w/ 30-day Readmission	1,842	18%	15%	17.4%		\sim

DM

Humedica MinedShare[®] – Typical Query

Even relatively complex clinical questions can be answered by point-and-click queries, since Humedica's disease models include variables that support typical clinical questions, including relevant lab values, clinical observations (BP, BMI), medication classes and subclasses, and resource measures for ambulatory care





Type 2 Diabetes: First Drug after Metformin

- Patients with type 2 diabetes
- At least 2 E&M visits in each of 2 successive years
- At least 14 months on metformin (only)...
 - Change in therapy
 - Continue metformin through end of data
- Choice of second drug, by A1c
 - Last A1c prior to change in therapy
 - Last A1c, if continuing on metformin
- By medical group
- All groups achieved similar improvement in glycemic control
 - Overall (by initial A1c)
 - By major subgroups—age, comorbidities, sociodemographic factors, "engagement" with medical group (visit frequency)

Break Out ΔRx Cohort by Drug Class

Proportion of patients at each initial A1c level receiving each drug class or combination

- All eRx activity within 30 days of ΔRx
- Overall, a "graded response" to initial A1c level



Prescribing Patterns Vary across Medical Groups

- Wide variation across groups in use of insulin, DPP-4 inhibitors, TZDs, and GLP-1 agonists
 - DPP-4i's cost approximately \$2,500 per year
- All groups achieved similar improvement in glycemic control



Prescribing Patterns Vary across Medical Groups

- Breaking out each group's prescribing by initial A1c, there is a "graded" response within many groups, but the drug choices vary across groups
- For each group, five bars, by initial A1c: 7–8%, 8–9%, 9–10%, 10–11%, ≥ 11%



Prevalence of Comorbidities

- Wide variation across medical groups in the proportion of active patients age 20–85 who have these chronic conditions
 - Important to account for these differences, in order to obtain valid, apples-to-apples comparisons
- Currently developing multiple regression models to adjust for differences in comorbidities and sociodemographic factors



Prevalence of Comorbidities in Patients with Diabetes

- Among patients with diabetes, there is a three-fold variation across groups in the prevalence of COPD and a four-fold variation in the prevalence of heart failure
- Among these patients, the prevalence of hypertension varies from 53 to 86%, dyslipidemia from 59 to 85%
- While high and low prevalence tends to be concentrated in certain groups, there are some differences across these conditions



Level of Education

- Distribution of patients by level of education in zip code of residence: Percent of persons age ≥ 25 with some high school
 - These data reflect 1.7 million patients with hypertension across 20 medical groups who had an E&M visit between Dec. 1, 2010 and Nov. 30, 2012
 - Variation across medical groups in in presumptive level of health literacy, based on imputed education level
- In three medical groups, approximately one-fourth of patients fall below the 10th percentile of the overall patient population



Rural–Urban Distribution

- Medical groups differ in the proportion of their patients who come from non-metropolitan zip codes
- 6.95 million patients, across 20 medical groups, with ambulatory E&M or Procedure visit during 2011 or 2012
 - Omits patients with zip codes that do not map to current RUCA tables





Copyright © 2013 Anceta LLC and Humedica Inc. All rights reserved.



Depression in Diabetes

Anxiety Diabetic neuropathy Fibromyalgia Post-herpetic neuralgia Osteoarthritis Lower back pain

21 medical groups — 566,000 patients in Humedica diabetes cohort, age 20–89, with E&M visit during 2012 Diabetes type 1, type 2, type unknown: Dx or Rx for depression in year prior to last E&M visit Within each medical group, bars represent 5-year age bands All Groups BA BY СВ DA DQ EW GB HV KT LA MB NE NQ PR QP TU VB WD YQ ZW тJ 100 % 100 % **Rx, Other Dx** 90 % 90 % Rx Dx, Rx 80 % 80 % Dx 70 % 70 % 60 % 60 % 50 % 50 % 40 % 40 % No Dx or Rx 30 % 30 % 20 % 20 % 10 % 10 % 0 % 0 %

Evidence for Diabetes

- 21 medical groups 510,000 patients in Humedica diabetes cohort, age 20–89, with E&M visit during 2012
- Across all groups, about 12% of patients with diabetes do not have a Dx on a claim or an EHR problem list entry



Performance over Time: Following a patient cohort over 3 years

- Diabetes Cohort
- Type 1, Type 2, Unknown

- E&M visit Dec 2009 Nov 2010 (year = 2010)
- At least one E&M visit in each of the next 2 years (2011, 2012)
- D3 Bundle: A1c < 8, LDL < 100, BP < 140/90
- Last values in each year





Visit Counts, by Patient Complexity

Patients with HTN, Age 18–85, E&M Visit 1/1/2012–7/31/2012, Patients of "Designated" Providers

Designated providers are those specified by the medical group whose patients are included on enterprise dashboard displays in Humedica MinedShare, generally providers associated with a "designed" primary care practice (e.g., a patient-centered medical home initiative).

Distrib of Pts. by Charlson Comorbidity Index



E&M Visit Count by Charlson Comorbidity Index



Uses of Regression Models

Who's getting the best outcomes,

after accounting for differences in patient populations?

First, account for patient factors:

- Age, gender, race/ethnicity
- Comorbid conditions
 - Overall disease burden
 - Specific diagnoses
 - Clinical data (e.g., eGFR, A1c, BP, BMI)
 - Smoking status
- Financial class (patient-specific)
- Imputed sociodemographic data (zip code)
 - Education, household income
 - Rural/urban

Then examine medical group effects who's doing best, on similar patients?

- Interview the "best" groups to learn what they're doing for these patients, and
- Use logistic regression to identify which care process factors are more associated with the group(s) who are doing best

What's different about patients

with good outcomes, compared to those with poor outcomes?

- Patient factors
- Process of care

Logistic regression – binary outcome

- Patient in control vs. out of control (last E&M)
- Patient moves into vs. out of control
- Patient has complete measures vs. not

What patient factors and which care process elements are associated with favorable outcomes or lower cost?

- Start with patient factors
- What care process elements have additional explanatory power?



VALUE-ADD PROCESS PLANKS

Blood Pressure Recording

Last BP for Patients Age 18–85 with E&M Visit 1/1/2012–7/31/2012, "Designated" Providers

Designated providers are those specified by the medical group whose patients are included on enterprise dashboard displays in Humedica MinedShare, generally providers associated with a "designed" primary care practice (e.g., a patient-centered medical home initiative) and identified as the patient's Current PCP in the EHR or practice management system or who provided the plurality of E&M services during the last full calendar year prior to the last E&M visit. (n = 309,000)



Blood Pressure Recording

Last BP for Patients Age 18-85 with E&M Visit 1/1/2012-7/31/2012, "Designated" Providers

Designated providers are those specified by the medical group whose patients are included on enterprise dashboard displays in Humedica MinedShare, generally providers associated with a "designed" primary care practice (e.g., a patient-centered medical home initiative) and identified as the patient's Current PCP in the EHR or practice management system or who provided the plurality of E&M services during the last full calendar year prior to the last E&M visit. (n = 309,000)





- JNC 7 recommendations:
 - Patients with diabetes or chronic kidney disease, BP < 130/80
 - All other patients, BP < 140/90



BP Control at Last E&M Visit: Complicated Patients

- Evidence of diabetes or chronic kidney disease (Dx/PL, lab, or meds): control threshold 130/80
- 488,000 patients with Dx/PL or BP evidence of hypertension and at least one E&M visit, 9/1/2011 8/31/2012
- All providers, 19 medical groups



HTN Control – Variation within a Medical Group

- Patients in hypertension cohort with at least one E&M visit between 12/01/2011-11/30/2012
- All family medicine or internal medicine sites of care with over 500 hypertension patients
- HTN control among patients with BP measured at last E&M visit
 - Evidence of diabetes or chronic kidney disease (Dx/PL, lab, or meds): BP < 130/80
 - All other patients: BP < 140/90



Typical Collaborative Meeting Topics

- Techniques for breakthrough improvement
 - Complexity theory
- Hypertension
 - Plank-by-plank dialogue
 - Presentations by groups with superior outcomes and costs
 - Exercise: Comparative data → Action plan
- Diabetes
 - Cost of medications for glycemic control
 - Reducing proportion of patients with incomplete measures
- "PCMH 2.0"
 - Staffing models
 - Which elements drive the value?
 - Can we do it more efficiently?
- Ambulatory intensive care
 - Risk stratification: Whom to target? When?
 - What disciplines/services are key?
 - How does it integrate with the rest of the system?